Asset Details
Do you wish to reserve the book?
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Do you wish to request the book?
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
2017
Overview
After nearly 11 years of follow-up, long-term administration of imatinib was shown to be associated with prolonged control of chronic myeloid leukemia and no cumulative or late toxic effects have emerged.
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm that is characterized by the Philadelphia (Ph) chromosome and driven by its product, the BCR-ABL1 tyrosine kinase.
1
In 2001, imatinib was introduced as a BCR-ABL1 tyrosine kinase inhibitor and was approved for the treatment of CML on the basis of a high level of activity in phase 2 studies.
2
Early results from the phase 3 International Randomized Study of Interferon and STI571 (IRIS) showed that imatinib at a dose of 400 mg once daily was more active and was associated with fewer side effects than interferon alfa plus cytarabine in patients with . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Cytarabine - therapeutic use
/ Female
/ Humans
/ Imatinib
/ Imatinib Mesylate - adverse effects
/ Imatinib Mesylate - therapeutic use
/ Interferon-alpha - therapeutic use
/ Kinases
/ Leukemia
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality
/ Male
/ Patients
/ Protein Kinase Inhibitors - therapeutic use
/ Survival
